Clinical trials in Sjögren’s disease have shown mixed results over the past decade, but new drugs in the pipeline are raising hopes for potential paradigm shifts in treatment. B-cell depletion therapies like rituximab have been studied, along with CD40 blockade and CAR T-cell therapy. While results have been mixed, researchers remain optimistic and emphasize the importance of early intervention in Sjögren’s management. Various drug trials targeting different pathways are ongoing, with some showing promise in improving symptoms and disease activity. However, experts caution against using the term “cure” and stress the need for more data and a cautious approach in treating Sjögren’s disease.
Source link
Potential Sjögren’s drugs may herald ‘paradigm shift’ to treating underlying processes
